

Factsheet



Acronym BIOMAP

Full title Biomarkers in Atopic Dermatitis and Psoriasis

Programme Horizon 2020-JTI-IMI2-2017-13-two-stage

Contract number 851511

**Abstract** Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 821511. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

**Duration** 60 months (01/04/2019 - 31/03/2024)

**Project funding** 21,953,308.79 €

**Coordinator** Prof. Stephan Weidinger  
Christian-Albrechts-Universität zu Kiel  
Kiel, Germany  
Email: [sweidinger@dermatology.uni-kiel.de](mailto:sweidinger@dermatology.uni-kiel.de)

- Partners**
- Christian-Albrechts-Universität zu Kiel, Germany
  - King's College London, United Kingdom,
  - Karolinska Institutet, Sweden
  - Academisch Ziekenhuis Leiden, The Netherlands
  - Université du Luxembourg, Luxembourg
  - Tampereen Yliopisto, Finland
  - Klinikum Rechts der Isar der Technischen Universität München, Germany
  - Ait - Austrian Institute of Technology GmbH, Austria
  - Universitätsklinikum Hamburg-Eppendorf, Germany
  - University of Bristol, United Kingdom
  - Københavns Universitet, Denmark
  - Den Selvejende Institution Dansk Børneastma Center, Denmark
  - Stichting Katholieke Universiteit, The Netherlands
  - Tartu Ülikool, Estonia
  - Centre Hospitalier Universitaire Vaudois, Switzerland
  - Itä-Suomen Yliopisto, Finland
  - Heinrich-Heine-Universität Düsseldorf, Germany
  - Trinity College Dublin, Ireland
  - Academisch Medisch Centrum bij de Universiteit van Amsterdam, The Netherlands
  - Information Technology for Translational Medicine sa, Luxembourg
  - Hahn-schickard-gesellschaft fuer angewandte Forschung e.v., Germany
  - London School of Hygiene and Tropical Medicine, United Kingdom
  - Eurice - European Research and Project Office GmbH, Germany
  - Universität Wien, Austria



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 821511. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

- Sanofi-Aventis Deutschland GmbH, Germany
- LEO Pharma as, Denmark
- Boehringer Ingelheim International GmbH, Germany
- Pfizer Limited, United Kingdom
- UCB Biopharma sprl, Belgium
- Technische Universität Muenchen, Germany
- Novartis Pharma AG, Switzerland
- Almirall S.A., Spain
- University of Edinburgh, United Kingdom

**Contact** Tamara Messer  
Project Manager  
Heinrich-Hertz-Allee 1  
D-66386 St. Ingbert, Germany  
Phone: +49 6894 388 13 30  
Email: t.messer@eurice.eu

**Website** [www.biomap-imi.eu](http://www.biomap-imi.eu)



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 821511. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.